Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) was filed on February 28, 2023, reporting an event that occurred on February 23, 2023. The report concerns the company's obligations under the Contingent Value Rights (CVR) Agreement related to the 2019 acquisition of Celgene Corporation, specifically regarding the Abraxane product.
Key Financial Metrics
- Abraxane Net Sales (2022): $908,974,933 for the year ended December 31, 2022.
- CVR Payment Due (2022): $0. The filing states there is no Net Sales Payment due for this period.
- Other Financials: The filing text does not provide a clear value for overall company revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
This filing represents a specific disclosure regarding the calculation of Net Sales for the Abraxane product for the 2022 measuring period. It confirms that sales levels did not trigger a payment obligation under the CVR Agreement for this specific year. No other material changes to the company's financial position are detailed in this document.
Guidance, Outlook, and Risks
The company reserves the right to disclose future Net Sales Payments for subsequent measuring periods via its investor website. The filing does not contain general business guidance, management commentary on future outlook, or a discussion of broader risks and contingencies beyond the specific CVR obligation.
Key Facts for Investor Verification
- Verify the definition of "Net Sales" in the CVR Agreement to understand the threshold for future payments.
- Monitor the company's investor website for disclosures regarding Net Sales Payments for subsequent years.
- Confirm that the $908.97 million figure represents the final audited Net Sales for Abraxane for the 2022 period.